Partial
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated claims align with many labeled adverse events and mechanism details but include several unsupported or incomplete statements. Notable gaps include contraindications (prior ACE inhibitor–associated angioedema and bilateral renal artery stenosis), pediatric safety/dosing, explicit first-dose safety guidance, comprehensive pregnancy management guidance, and explicit hyperkalemia monitoring details. Several claims also overreach (e.g., exact incidence figures not stated in the label) or misstate incidences for certain adverse events.
Category Scores
MonitoringRecommendations
85
Accurate Statements
Headache (up to 6%) is a side effect of lisinopril.
Adverse Reactions, t300
Cough (up to 3-4%) is a side effect of lisinopril.
Adverse Reactions, t300; Mechanism of Action
Angioedema involves swelling of the face, lips, tongue, or throat.
WARNINGS, Angioedema
Angioedema can be life-threatening and requires immediate medical attention.
WARNINGS, Angioedema
Angioedema incidence is higher in Black patients.
WARNINGS, Angioedema
Pregnancy is contraindicated due to fetal harm (Category D).
USE IN PREGNANCY
Cough often resolves by switching to an ARB like losartan.
Information for Patients
Monitor blood pressure and potassium regularly.
PRECAUTIONS
Stop lisinopril and seek emergency care for angioedema symptoms like difficulty breathing or swallowing.
WARNINGS, Angioedema
Report persistent dizziness or fatigue to a doctor—dose adjustment or alternatives may help.
Information for Patients
Lisinopril blocks angiotensin-converting enzyme.
Mechanism of Action
Lisinopril raises bradykinin levels.
Mechanism of Action
Raising bradykinin levels is linked to cough and angioedema.
Mechanism of Action
Lisinopril alters kidney blood flow (risking hyperkalemia or impairment).
Mechanism of Action; Renal Effects
Unsupported Statements
Lisinopril, an ACE inhibitor used for high blood pressure and heart failure.
Indication for the lisinopril+HCTZ product is hypertension; heart failure is not listed in the provided Indications and Usage for this product.
Dizziness (up to 19% of patients) is a side effect of lisinopril.
Label data show dizziness with lower incidence (e.g., table t300 for combination lists 7.5%), not 19%.
Fatigue (up to 3%) is a side effect of lisinopril.
Adverse events in the label show fatigue around 3.7% for the lisinopril+HCTZ combination.
Nausea (up to 2%) is a side effect of lisinopril.
Nausea incidence in the label’s adverse event table is around 2.2–2.5% for the combination, not exactly 2%.
Persistent dry cough affects 5-20% long-term, often leading to discontinuation.
The label lists cough but does not specify 5-20% long-term or discontinuation rates; the provided figures differ.
Palpitations occur (1-2%).
Palpitations are not enumerated among the common adverse events in the provided label excerpt.
Hyperkalemia occurs in 1-2% of cases, especially with kidney issues or potassium supplements.
Exact incidence figure 1-2% is not stated in the provided label excerpt; hyperkalemia risk is described but the numeric incidence is not specified here.
Kidney function can worsen (1-2%).
Label indicates renal impairment risk but exact 1-2% figure is not specified in the provided excerpt.
Stevens-Johnson syndrome is rare.
SJS is listed as a rare adverse reaction in the label; this statement is generally consistent with labeling.
Diabetes increases risk of hypotension and kidney issues.
The label discusses comorbidity considerations but does not quantify a diabetes-specific increase in these risks in the provided excerpt.
On diuretics increases risk of hypotension and kidney issues.
The label notes increased risk with concomitant diuretic use; exact phrasing in the provided excerpt supports this.
Contradictions
Low
AI Statement
Dizziness (up to 19% of patients) is a side effect of lisinopril.
Label Reference
Adverse Reactions; t300
Low
AI Statement
Fatigue (up to 3%) is a side effect of lisinopril.
Label Reference
Adverse Reactions; t300
Low
AI Statement
Nausea (up to 2%) is a side effect of lisinopril.
Label Reference
Adverse Reactions; t300
Low
AI Statement
Persistent dry cough affects 5-20% long-term, often leading to discontinuation.
Label Reference
Adverse Reactions; Mechanism of Action
Low
AI Statement
Palpitations occur (1-2%).
Label Reference
Adverse Reactions; t300
Low
AI Statement
Diabetes increases risk of hypotension and kidney issues.
Label Reference
INDICATIONS AND USAGE
Low
AI Statement
On diuretics increases risk of hypotension and kidney issues.
Label Reference
INDICATIONS AND USAGE
Low
AI Statement
Pregnancy is contraindicated due to fetal harm (Category D).
Label Reference
USE IN PREGNANCY
Important Omissions
Explicit contraindications for prior ACE inhibitor–associated angioedema and for bilateral renal artery stenosis.
Importance:
High
Pediatric safety and dosing guidance (pediatric use for hypertension; not established for all indications; age thresholds).
Importance:
High
Dosing safety specifics: first-dose hypotension and required monitoring with initiation or dose titration guidance.
Importance:
High
Pregnancy management specifics beyond risk (alternatives if pregnancy occurs, contraception considerations, and fetal risk categorization).
Importance:
High
Hyperkalemia risk mitigation with CKD, potassium-sparing drugs, or concomitant ACE inhibitors/diuretics; explicit monitoring recommendations.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Label acknowledges common adverse events and major warnings (angioedema, hyperkalemia, hypotension) with monitoring; no indication of untenable safety concerns beyond standard ACE inhibitor use.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Important safety gaps identified (contraindications, pediatric use, first-dose/dosing monitoring, comprehensive pregnancy guidance, hyperkalemia mitigation) that would need explicit labeling to be fully aligned.
Suggested Improvement
If generating an AI answer, ensure statements explicitly map to the label sections:Indications (hypertension, not heart failure in lisinopril+HCTZ), Contraindications (prior ACE inhibitor–associated angioedema, bilateral renal artery stenosis), Boxed warning for pregnancy, Hyperkalemia monitoring, First-dose hypotension guidance, Pediatric use, and detailed monitoring recommendations.